Biomarkers and potential targets for immune and cellular therapy in triple negative breast cancer

Cellular Therapy and Transplantation

article

Oleg E. Molchanov¹  Dmitrii A. Maistrenko¹  Dmitrii A. Granov¹  Lubov V. Vasina²  Alena A. Popova¹  Irina V. Vasilevskaya¹  Olga V. Mikolaichuk¹  Olga S. Shemchuk²  Elena A. Popova¹  Alexandra V. Protas¹  Vladimir V. Sharoyko¹  Konstantin N. Semenov¹ 

[1] A.M. Granov Russian Research Centre for Radiology and Surgical Technologies;Pavlov University;Institute of Chemistry, St. Petersburg State University

关键词: Breast cancer;    triple negative;    molecular subtypes;    mutational burden;    tumor stem cells;    circulating tumor cells;    cellular microenvironment;    lymphocyte subpopulations;    interleukins;    molecular targets;    cellular therapy.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-2-16-30

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Triple negative breast cancer (TNBC) is the most aggressive variant of breast malignancies, being a heterogeneous group with various molecular abnormalities that require differentiated approach to diagnosis and treatment. The article contains current data on modern molecular classifications of triple negative breast cancer and appropriate defects in signaling pathways as well as their assignment to distinct immunological and metabolic biomarkers. The data on the prognostic and predictive role of the tumor molecular biomarkers, as well as on clinically used and cellular therapy approaches and developing targeted drugs are presented, and the prospects for the future research are outlined. We also present the data of our own research concerning evaluation of the prognostic role of cytokines and lymphocyte subpopulations in peripheral blood of the TNBC patients.

【 授权许可】

CC BY